How Chinese pharmaceutical industry get out of current predicament

Chinese pharmaceutical industry has ever experienced a great period of the 1990s. In this period, China's pharmaceutical raw materials industry successfully undertakes the industrial transfer of the U.S., Japan, Switzerland, Italy, Spain and European countries. In the short span of 10 years, China's pharmaceutical industry achieves the rapid development. The pharmaceutical industry had finished the waking time that developed countries went for nearly 60 years. It has laid a solid foundation for China to become the world's largest pharmaceutical raw materials producing and exporting countries.

According to statistics, China has been able to produce over 1500 kinds of chemical raw materials. Production of pharmaceutical raw materials are up to 1.23 million tons in 2005 (excluding chemical intermediates and precursor drugs), some products still has a pivotal role in the international market. For example, penicillin industrial salt, vitamin C, cephalosporin C, too, erythromycin, tetracycline and other fermented primary products, chemical synthetic drugs, pharmaceutical raw materials such as caffeine, acetaminophen, aspirin, and quinolone The antibiotics norfloxacin, ciprofloxacin, ofloxacin, according to the production of enoxacin, also ranks first in the world.

However, production and management advantages of China's pharmaceutical industry are also subject to challenges from the rest of the world pharmaceutical raw materials glutathione in emerging countries and regions. The strongest rival is India. They are the same premium Competition of the way, and China in the international market continue to compete on price, after years of battle and fight to fight, China Pharmaceutical prices in the international market is becoming less and less, a lot of varieties in almost unprofitable proportions. Summary of the Chinese Pharmaceutical industry we have taken this journey, the Chinese Pharmaceutical industry during the golden age of gold.

In a sense, China is simply to undertake the transfer of industries in the United States, Japan, Switzerland, Italy, Spain and other developed countries and European countries, and not too high technological content and high-tech, the contrary, the Chinese also developed countries Pharmaceutical industry, pollution, garbage, or simply repeat the introduction of the developed countries purchase low price the overdraft environment to bear the expense of the bottom line capacity production of pharmaceutical raw resveratrol products at the same, yet the pollution never left China. Resulting in the China National Pharmaceutical industry in a very vulnerable position, if there are competitors from other countries and regions, China's pharmaceutical industry advantage will be depleted.

At the same time, in face of this low-cost challenge from the foreign emerging pharmaceutical raw materials production, as well as anti-dumping lawsuits from the developed countries, China's pharmaceutical industry withstands adverse state surrounded by the enemy. Therefore, China national pharmaceutical industry should assess and review about the changed from golden era to the present recession or low profits extraordinary journey. China national pharmaceutical industry need transition facing the changing and diverse international markets. Otherwise, China can only maintain low-level position in the international pharmaceutical raw materials market and will always miss the name of power country in pharmaceutical raw materials.

Source:http://www.cospcn.com